0001493152-21-010808.txt : 20210507
0001493152-21-010808.hdr.sgml : 20210507
20210507192342
ACCESSION NUMBER: 0001493152-21-010808
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210506
FILED AS OF DATE: 20210507
DATE AS OF CHANGE: 20210507
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: 22NW, LP
CENTRAL INDEX KEY: 0001694297
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40388
FILM NUMBER: 21904772
BUSINESS ADDRESS:
STREET 1: 1455 NW LEARY WAY, SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98107
BUSINESS PHONE: 206-437-9174
MAIL ADDRESS:
STREET 1: 1455 NW LEARY WAY, SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: English Aron R.
CENTRAL INDEX KEY: 0001770436
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40388
FILM NUMBER: 21904773
MAIL ADDRESS:
STREET 1: 1455 NW LEARY WAY, SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Anebulo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001815974
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851170950
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201
CITY: LAKEWAY
STATE: TX
ZIP: 78734
BUSINESS PHONE: 737 203 5270
MAIL ADDRESS:
STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201
CITY: LAKEWAY
STATE: TX
ZIP: 78734
4
1
ownership.xml
X0306
4
2021-05-06
0
0001815974
Anebulo Pharmaceuticals, Inc.
ANEB
0001770436
English Aron R.
C/O ANEBULO PHARMACEUTICALS, INC.
1415 RANCH ROAD 620 SOUTH, SUITE 201
LAKEWAY
TX
78734
1
0
1
1
See Explanation of Responses
0001694297
22NW, LP
1455 NW LEARY WAY, SUITE 400
SEATTLE
WA
98107
0
0
1
1
See Explanation of Responses
Common Stock, par value $0.001 per share
2021-05-06
4
A
0
714286
7.00
A
3343601
I
22NW, LP
Common Stock, par value $0.001 per share
4654528
I
Pharma Investors, LLC
This Form 4 is filed jointly by Aron R. English and 22NW, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by 22NW, LP. Mr. English, as the President of 22NW, LP, may be deemed to beneficially own the securities owned directly by 22NW, LP.
Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC.
Please note that this Form 4 corrects information that was previously reported on the Reporting Persons' Form 3 filed with the U.S. Securities and Exchange Commission on May 6, 2021 (the "Form 3"). Footnote 3 of the Form 3 is hereby corrected to state that Mr. English is the owner of Pharma Investors, LLC, not the owner of 22NW, LP.
/s/ Rex Merchant, as Attorney-in-Fact
2021-05-07
22NW, LP; By: /s/ Rex Merchant, as Attorney-in-Fact
2021-05-07